Was appointed by President Obama to the National Cancer Advisory Board.
Recipient of the Breakthrough Prize in Life Sciences that recognizes "excellence in research
aimed at curing intractable diseases and extending human life."
Recipient of the Lasker DeBakey Clinical Medical Research Award.
Played a key role in the development of imatinib (Gleevec) and dasatinib (Sprycel), two drugs
that together have transformed chronic myelogenous leukemia from a fatal cancer into one
that is nearly always treatable.
Helped design the first clinical trial for imatinib, including selecting which patients were
most likely to benefit from the drug.
Leading a team that uses a new approach in finding a potential drug to attack cancer cells
that have become resistant to enzalutamide (Xtandi), a targeted therapy for the treatment of
advanced prostate cancer.